Europe Gene Therapy Market to Reach USD 8.78 Billion by 2033 | EMA Support, One-Time Curative Treatments & CRISPR Innovation Drive 24.9% CAGR

The Europe Gene Therapy Market size reached USD 1,030.70 million in 2024 and is projected to reach USD 8,780.77 million by 2033, growing at a CAGR of 24.9% from 2025 to 2033. This robust growth is driven by the rising prevalence of rare and genetic diseases affecting millions across the EU and UK, strong regulatory support from the EMA facilitating approvals, substantial public and private investments in R&D and manufacturing, advancements in viral vectors and gene editing technologies like CRISPR, expanding clinical pipelines for one-time curative treatments, and increasing demand for precision medicine targeting oncology, rare diseases, and neurological conditions.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-
https://www.datamintelligence.com/download-sample/europe-gene-therapy-market?sindhuri

Key Industry Developments
✅ November 2025: Ferring Pharmaceuticals strengthened European supply chains with a new manufacturing facility for gene therapies, enhancing access to treatments like those for bladder cancer.
✅ October 2025: Ongoing expansions in clinical trials across France, Italy, and the Netherlands advanced therapies for rare syndromes like Crigler-Najjar.
✅ July 2025: European Commission granted conditional authorization for Pfizer's DURVEQTIX, a one-time gene therapy for hemophilia B, broadening treatment options.

Key Mergers and Acquisitions/Ininvestments (2025):
✅ Roche invests in German gene therapy center: In March 2024 (ongoing impact 2025), Roche committed US$ 94 million to a development center near Munich, supported by Germany's US$ 46 million national strategy for gene and cell therapies.
✅ Strategic partnerships and facility expansions: Companies like CSL and Spark Therapeutics advanced European manufacturing and commercialization through investments and collaborations.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=europe-gene-therapy-market?sindhuri
(Purchase 2 or more Reports and get 50% Discount)

Market Segmentation Analysis:
-By Approach: In-Vivo Leads with Dominant Share
The In-Vivo segment commands the largest market share (valued at US$ 916.93 million in 2024, projected to US$ 8,071.46 million by 2033 at 25.3% CAGR), driven by direct genetic material delivery enabling targeted treatment for monogenic disorders and rare diseases, supported by EMA approvals like Zolgensma.
Ex-Vivo approaches support specialized applications but grow slower.
-By Vector Type: Viral Vectors Command Largest Portion
Viral Vectors dominate due to efficient delivery and established use in approved therapies.
Non-Viral Vectors are emerging for improved safety profiles.
-By Application: Rare Diseases Top with Strong Demand
Rare Diseases remain foundational, fueled by high unmet needs and orphan designations.
Oncology and Ophthalmology are high-growth areas with advancing pipelines.

Growth Drivers:
High Prevalence of Rare and Genetic Diseases - Affecting up to 36 million in the EU, driving demand for curative options.
Strong Regulatory Framework and Approvals - EMA's supportive pathways accelerate market entry.
Robust Investments and National Strategies - Public funding (e.g., Germany's initiative) and private commitments boost infrastructure.
Advancements in Technologies - CRISPR, CAR-T, and improved vectors enable precision treatments.
Shift to One-Time Curative Therapies - Reducing long-term costs for chronic conditions.

Speak to Our Analyst and Get Customization in the report as per your requirements:
https://www.datamintelligence.com/customize/europe-gene-therapy-market?sindhuri

Regional Insights:
Europe leads in gene therapy innovation and adoption, driven by a mature regulatory environment (EMA), high rare disease burden (e.g., 3-3.5 million cases in UK/France/Spain), concentrated R&D hubs in Germany and the UK, and cross-border collaborations facilitating clinical trials and commercialization. Key countries like Germany, France, Italy, Spain, and the UK benefit from national strategies and investments, positioning the region as a global pioneer despite high treatment costs.

Key Players:
Novartis AG | Sarepta Therapeutics, Inc. | CSL | Bluebird Bio, Inc. | Spark Therapeutics, Inc. | Ferring | Vertex Pharmaceuticals Incorporated | Amgen, Inc. | BioMarin Pharmaceutical Inc. | CRISPR Therapeutics | Alnylam Pharmaceuticals, Inc. | Orchard Therapeutics Plc | MeiraGTx Holdings plc | PTC Therapeutics, Inc.

Key Highlights (Top 5 Key Players) for Europe Gene Therapy Market:
1. Novartis AG maintains leadership with approved therapies like Zolgensma, leveraging strong EMA pathways for rare disease treatments.
2. Spark Therapeutics (Roche) excels in ophthalmology gene therapies, supported by European manufacturing investments.
3. CSL advances hemophilia treatments like HEMGENIX, gaining conditional authorizations for broader access.
4. BioMarin Pharmaceutical Inc. differentiates in rare genetic disorders with established European approvals and pipelines.
5. CRISPR Therapeutics innovates in gene editing, targeting high-impact applications in oncology and rare diseases.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sindhu

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.